How Retatrutide Works: GLP-1, GIP & Glucagon Receptor Mechanisms
Quick Answer: How Does Retatrutide Work?
Retatrutide (LY3437943) is a synthetic peptide engineered to bind and activate three distinct G-protein-coupled receptors simultaneously: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. This is what makes it a "triple agonist" — it turns on all three receptor "locks" at once, using a single peptide molecule with structural features designed to interact with each receptor's binding site.
In preclinical research models, each of the three receptors is involved in a different aspect of metabolic signalling. The GLP-1 receptor is linked to insulin secretion and appetite signalling in the brain. The GIP receptor is linked to insulin secretion in the pancreas and signalling in fat tissue. The glucagon receptor is linked to hepatic (liver) glucose output and energy expenditure. By activating all three simultaneously, retatrutide introduces a mechanistic complexity that single-agonist compounds like semaglutide and dual-agonist compounds like tirzepatide cannot replicate.
All of the above are research observations from preclinical and Phase 1/2 study literature — not claims about human therapeutic effects.
What Is Receptor Agonism?
A receptor is a protein on the surface (or inside) of a cell. When a specific molecule — the right "key" — binds to the receptor, it changes the receptor's shape and triggers a chain of signals inside the cell. A molecule that binds to a receptor and switches it on is called an agonist.
The receptors targeted by retatrutide are all G-protein-coupled receptors (GPCRs) — a large family of receptor proteins that pass signals across the cell membrane by activating internal G-proteins, which in turn trigger cascades of downstream signalling events (changes in cAMP, PKA activation, CREB phosphorylation, and more). GPCRs are the target of a large proportion of currently investigated pharmaceutical compounds.
Retatrutide was designed with a single backbone peptide chain that has distinct structural regions capable of binding each of the three receptor types. Binding affinity data from Coskun et al., 2022 (Cell Metabolism) confirmed receptor-level activity at all three targets, with selectivity profiles characterised across GIP, GLP-1 and glucagon receptors in in vitro binding assays.[1]
The GLP-1 Receptor Pathway
GLP-1 (Glucagon-Like Peptide-1) is a gut hormone naturally released after eating. GLP-1 receptors are found in pancreatic beta cells, the brain (hypothalamus and brainstem), the heart, and the gut. In preclinical research models, GLP-1 receptor activation is linked to: (1) glucose-dependent insulin secretion from pancreatic beta cells; (2) inhibition of glucagon secretion from pancreatic alpha cells; (3) slowing of gastric emptying; and (4) appetite-suppression signals in the central nervous system.[2]
The GLP-1 pathway is the most extensively studied of the three. Semaglutide (Ozempic/Wegovy) is a selective GLP-1 receptor agonist. Tirzepatide (Mounjaro) adds GIP but retains GLP-1 as a core mechanism. Retatrutide incorporates GLP-1 agonism as the first of its three receptor targets.
In the context of retatrutide's triple-agonist structure, the GLP-1 component is thought to contribute primarily to the insulin secretion and appetite-signalling axes in the published research models. Müller et al. (2019) provide a comprehensive review of GLP-1 receptor biology across tissues, which forms part of the research foundation for understanding how triple-agonist compounds engage this pathway.[2]
The GIP Receptor Pathway
GIP (Glucose-Dependent Insulinotropic Polypeptide) is a hormone secreted by K-cells in the small intestine after eating. GIP receptors are expressed in pancreatic beta cells, adipose (fat) tissue, bone, and the central nervous system. In preclinical research models, GIP receptor activation is linked to: (1) glucose-dependent insulin secretion from beta cells (amplifying the GLP-1 effect); (2) signalling in adipose tissue related to lipid handling; and (3) potential central appetite signalling.[3]
For many years, GIP was investigated as a target independently. The dual-agonist approach (GLP-1 + GIP together) was first characterised in detail by Finan et al. in 2013, who showed that a single molecule activating both receptors produced greater effects in rodent models than either agonist alone — suggesting the pathways interact synergistically rather than simply additively.[3]
In retatrutide's structure, the GIP component sits alongside the GLP-1 component, potentially contributing to insulin secretion in an amplified way. Coskun et al. (2022) characterised the GIP binding affinity of LY3437943 and demonstrated co-engagement of the GIP and GLP-1 pathways in vitro, with subsequent in vivo characterisation in diet-induced obese mouse models.[1]
The Glucagon Receptor Pathway
Glucagon is a hormone secreted by pancreatic alpha cells that raises blood glucose by stimulating the liver to release stored glucose (glycogenolysis and gluconeogenesis). Glucagon receptors are expressed primarily in hepatocytes (liver cells), but also in the kidneys, adipose tissue, heart, and brain. In preclinical research models, glucagon receptor activation is additionally linked to: increased energy expenditure (thermogenesis) and modulation of hepatic lipid metabolism.[4]
On its own, glucagon receptor agonism raises blood glucose — which appears contradictory for a metabolic research compound. The mechanistic rationale for including it in a triple agonist is that when the GLP-1 and GIP components simultaneously stimulate insulin secretion (which lowers blood glucose), the glucose-raising effect of the glucagon component is counterbalanced. What remains, researchers hypothesise, is the energy-expenditure and hepatic fat-modulating effects of glucagon receptor activation — without the net hyperglycaemic effect seen with isolated glucagon agonism.
This hypothesis was first tested systematically by Day et al. (2009) in a co-agonist framework in rodent models,[4] and subsequently by Pocai et al. (2012) and others. Retatrutide represents the first triple GIP/GLP-1/glucagon receptor agonist to be studied in this framework at clinical trial scale — making the glucagon receptor the distinguishing feature that differentiates it from tirzepatide (which does not engage the glucagon receptor).
Why Three Receptors Together?
The scientific rationale for combining all three receptor agonisms in a single molecule is that the three pathways address different aspects of metabolic signalling simultaneously — and may interact synergistically rather than simply additively in research models.
| Receptor | Primary research-model links | Unique contribution vs dual-agonist |
|---|---|---|
| GLP-1 | Insulin secretion, appetite signalling, gastric emptying | Shared with tirzepatide |
| GIP | Insulin secretion amplification, adipose tissue signalling | Shared with tirzepatide |
| Glucagon | Energy expenditure (thermogenesis), hepatic glucose/lipid signalling | Unique to retatrutide — not in dual agonists |
Coskun et al. (2022) characterised the full receptor profile of LY3437943 and concluded that adding the glucagon receptor component to the GIP/GLP-1 framework produced measurable additional effects in preclinical models beyond what was seen with the GIP/GLP-1 dual framework alone. The authors proposed that the glucagon receptor agonism introduced an energy-expenditure axis that contributed to outcomes in the diet-induced obese mouse model studied.[1]
It is important to note that these are preclinical observations in rodent models. Whether the mechanistic interactions translate comparably to in vitro human cell systems or clinical outcomes is a separate research question — one that Phase 2 and planned Phase 3 trials are designed to investigate.
Key Published Research
This foundational study characterised the receptor binding profile and in vivo pharmacology of LY3437943. Using receptor binding assays, the authors demonstrated that the compound binds all three target receptors (GIP, GLP-1, glucagon) with activity confirmed by functional cAMP assays. In diet-induced obese (DIO) mice, the compound produced weight change and glucose tolerance changes greater than a comparable dual GLP-1/GIP agonist, with the authors attributing this in part to the glucagon receptor component's energy expenditure contribution. Non-human primate pharmacokinetic data confirmed a half-life supporting once-weekly dosing.
PMID: 35108511 — Cell Metab. 2022;34(6):882–898.e6
This Phase 1b study confirmed that receptor engagement observed in preclinical models translated to measurable pharmacokinetic activity in human participants. The study characterised LY3437943's mean half-life at approximately 7 days, supporting a once-weekly dosing regimen. Pharmacokinetic data showed dose-proportional exposure. The study confirmed that the triple-agonist mechanism as characterised in cell systems was maintained in vivo at the pharmacokinetic level.
PMID: 36356631 — Lancet. 2022;400(10366):1869–1881
Velox Peptides Supply Information
Supplied as a research reagent only. Not a medicine. Not evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy.
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(6):882–898.e6. PMID: 35108511
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PMID: 30120083
- Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151. PMID: 24174327
- Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749–757. PMID: 19597484
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b study. Lancet. 2022;400(10366):1869–1881. PMID: 36356631
Frequently Asked Questions
How does retatrutide work?
Retatrutide (LY3437943) works by simultaneously activating three G-protein-coupled receptors: GLP-1, GIP and glucagon. In preclinical research models, GLP-1 activation is linked to insulin secretion and appetite signalling; GIP activation is linked to insulin secretion amplification and fat-tissue signalling; glucagon activation is linked to hepatic glucose output and energy expenditure. All are research observations, not therapeutic claims.
What is the difference between single, dual and triple receptor agonism?
A single agonist (e.g. semaglutide) activates one receptor — GLP-1. A dual agonist (e.g. tirzepatide) activates two — GLP-1 and GIP. A triple agonist (e.g. retatrutide) activates all three — GLP-1, GIP and glucagon. Each additional receptor introduces a further mechanistic axis for researchers to study in preclinical models.
Why does retatrutide include glucagon receptor agonism?
The glucagon receptor adds a third mechanistic pathway — energy expenditure and hepatic lipid signalling — not present in GLP-1 or GLP-1/GIP dual agonists. Researchers hypothesise that when the GLP-1 and GIP components provide insulin secretion to balance blood glucose, the glucagon component may contribute additional energy-expenditure signalling. All preclinical observations — not therapeutic claims.
How is retatrutide different from tirzepatide mechanistically?
Tirzepatide activates GLP-1 and GIP receptors only (dual agonist). Retatrutide adds a third receptor — the glucagon receptor — to the same framework. The glucagon receptor targets hepatic glucose metabolism and energy expenditure, signalling pathways that tirzepatide does not engage. This is the core mechanistic distinction between the two compounds in published research literature.
Is retatrutide legal to buy in the UK for research?
Yes. Retatrutide is legal to purchase in the UK for in vitro research use only. It is not a licensed medicine and is not approved for human use. Velox Peptides supplies it strictly as a research reagent under our Research Use Policy.
What purity is Velox Peptides retatrutide?
Velox Peptides retatrutide is HPLC-verified at ≥99% purity by an independent third-party laboratory. A certificate of analysis is available with every order, or on request prior to ordering — email support@veloxpeps.com.
